Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next step toward track and trace requirements taken

Executive Summary

FDA's recently issued draft guidance on what should be included as part of a package-level standardized numerical identifier serves "an initial step to facilitating other measures for securing the drug supply chain" based on requirements included in the FDA Amendments Act. The agency is seeking comment on guidance that describes the SNI as being composed of the National Drug Code "that reflects each corresponding manufacturer or repackager, combined with a unique eight-digit numerical serial number generated by the manufacturer or repackager for each individual package." FDA says this identification "can in turn facilitate authentication and tracking and tracing of the prescription drugs." FDAAA requires the implementation of an SNI no later than 30 months after its Sept. 27, 2007 enactment. FDA's guidance does not address technologies that would be used to read the identifier. In March 2008 FDA requested public input on the status of e-pedigree technology and standards development (1"The Pink Sheet," March 31, 2008, p. 20). Comments on the draft guidance are due April 16
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS050660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel